Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-(3-bromo-2-naphthyl)-1,3,5-triazine-2,4-diamine is a synthetic small molecule belonging to the triazine class and naphthalene derivatives. It is primarily studied as an experimental compound and has been identified as an "inhibitor of heat shock protein HSP90 (both alpha and beta isoforms). HSP90 is a molecular chaperone involved in the folding and stabilization of many proteins required for tumor growth; thus inhibition of HSP90 can disrupt multiple signaling pathways in cancer cells. This compound has not been approved for clinical use but serves as a tool molecule in research settings focused on cancer biology and drug discovery[1][8][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-(3-bromo-2-naphthyl)-1,3,5-triazine-2,4-diamine.